Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.

ABSTRACT:

Objective

Lamotrigine trial in SPMS was a randomised control trial to assess whether partial blockade of sodium channels has a neuroprotective effect. The current study was an additional study to investigate the value of neurofilament (NfH) and other biomarkers in predicting prognosis and/or response to treatment.

Methods

SPMS patients who attended the NHNN or the Royal Free Hospital, UK, eligible for inclusion were invited to participate in the biomarker study. Primary outcome was whether lamotrigine would significantly reduce detectable serum NfH at 0-12, 12-24 and 0-24 months compared to placebo. Other serum/plasma and CSF biomarkers were also explored.

Results

Treatment effect by comparing absolute changes in NfH between the lamotrigine and placebo group showed no

SUBMITTER: Gnanapavan S 

PROVIDER: S-EPMC3731296 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature